UNSPSC 51112607: Nimustine

This classification denotes a nitrosourea compound with the molecular formula C9H13ClN6O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0S726V972K, chemically known as urea, n-((4-amino-2-methyl-5-pyrimidinyl)methyl)-n-(2-chloroethyl)-n-nitroso- but more generally known as nimustine, which bears US NIH Compound Identifier 39214. European Medicines Agency schedules Nimustine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09299MIG.

UNSPSC 51112607 Nimustine, a Commodity code, addresses pharmaceutical products for state and local health agencies, specifically specialty pharmaceuticals procured through direct-to-manufacturer and pharmacy benefit channels. State and local health departments and human services commissions are the primary issuing bodies under this code, purchasing prescription medications and related pharmacy services to support employee health plans, Medicaid programs, and institutional healthcare delivery. The scope spans specialty drugs like nimustine alongside broader pharmacy benefit management arrangements, including direct contracting models that bypass traditional pharmacy benefit managers and group purchasing organizations.

The Texas Health and Human Services Commission issued a Request for Information (RFI) No. HHS0017013, posted April 3, 2026, with a response deadline of April 3, 2026, to gather vendor capabilities and market intelligence on a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program. This RFI sought vendor experience with direct contracting for self-insured employers and health plans, flexibility to negotiate contracts using negotiated net pricing models without rebates, and capacity to implement value-based or outcomes-based agreements. The solicitation represents Texas HHS's preliminary information-gathering phase before issuing formal procurement documents with established financial and temporal parameters. No budget allocation, award value, or set-aside designation was identified in the RFI materials, as the state was conducting foundational research on vendor capabilities and direct-to-manufacturer program feasibility. Texas appears as the primary recent activity in this code space; geographic spread and repeat issuing bodies across additional jurisdictions are not supported by current opportunity records.